- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT07441694
Undersøgelse af INCA036978 hos deltagere med myeloproliferative neoplasi
En fase 1, åben-label, multicenterstudie af INCA036978 hos deltagere med myeloproliferative neoplasi
This study will be conducted to determine the safety, tolerability, dose-limiting toxicity (DLT)s, and maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE)s of INCA036978 administered as monotherapy and in combination with a standard disease-directed therapy.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Fase 1
Kontakter og lokationer
Studiekontakt
- Navn: Incyte Corporation Call Center (US)
- Telefonnummer: 1.855.463.3463
- E-mail: medinfo@incyte.com
Undersøgelse Kontakt Backup
- Navn: Incyte Corporation Call Center (ex-US)
- Telefonnummer: +800 00027423
- E-mail: eumedinfo@incyte.com
Studiesteder
-
-
New South Wales
-
Concord, New South Wales, Australien, 02139
- Rekruttering
- Concord General Repatriation Hospital
-
St Leonards, New South Wales, Australien, 02065
- Rekruttering
- Royal North Shore Hospital
-
-
Queensland
-
Auchenflower, Queensland, Australien, 04066
- Rekruttering
- Icon Cancer Centre
-
-
Victoria
-
East Melbourne, Victoria, Australien, 03002
- Rekruttering
- Epworth Health Care
-
-
Western Australia
-
Nedlands, Western Australia, Australien, 06009
- Rekruttering
- Linear Clinical Research
-
-
-
-
-
Liège, Belgien, 04000
- Ikke rekrutterer endnu
- Centre Hospitalier Universitaire (Chu) de Liege
-
Roeselare, Belgien, 08800
- Ikke rekrutterer endnu
- AZ DELTA
-
-
-
-
Ontario
-
Toronto, Ontario, Canada, M5G 2M9
- Rekruttering
- Princess Margaret Cancer Centre
-
-
Quebec
-
Montreal, Quebec, Canada, H3T 1E2
- Ikke rekrutterer endnu
- McGill University Jewish General Hospital
-
-
-
-
-
London, Det Forenede Kongerige, SE1 9RT
- Ikke rekrutterer endnu
- Guy'S Hospital - Guy'S & St Thomas' Nhs Foundation Trust
-
Nottingham, Det Forenede Kongerige, NG5 1PB
- Ikke rekrutterer endnu
- Nottingham University Hospitals
-
Oxford, Det Forenede Kongerige, OX3 7LE
- Rekruttering
- University of Oxford
-
-
-
-
Alabama
-
Birmingham, Alabama, Forenede Stater, 35233
- Ikke rekrutterer endnu
- University of Alabama At Birmingham
-
-
California
-
Irvine, California, Forenede Stater, 92618
- Rekruttering
- City of Hope-Lennar Foundation Cancer Center
-
Los Angeles, California, Forenede Stater, 90095
- Ikke rekrutterer endnu
- UCLA Medical Hematology & Oncology
-
Los Angeles, California, Forenede Stater, 90033
- Ikke rekrutterer endnu
- Usc Norris Comprehensive Cancer Center
-
-
Connecticut
-
New Haven, Connecticut, Forenede Stater, 06510
- Ikke rekrutterer endnu
- Yale Cancer Center
-
-
Florida
-
Miami, Florida, Forenede Stater, 33136
- Ikke rekrutterer endnu
- University of Miami
-
Tampa, Florida, Forenede Stater, 33612
- Ikke rekrutterer endnu
- Moffitt Cancer Center
-
-
Georgia
-
Atlanta, Georgia, Forenede Stater, 30322
- Rekruttering
- Winship Cancer Institute of Emory University
-
-
Maryland
-
Baltimore, Maryland, Forenede Stater, 21287
- Ikke rekrutterer endnu
- John Hopkins Hospital
-
-
Massachusetts
-
Boston, Massachusetts, Forenede Stater, 02114
- Rekruttering
- Massachusetts General Hospital
-
-
Missouri
-
St Louis, Missouri, Forenede Stater, 63108
- Ikke rekrutterer endnu
- Washington University School of Medicine
-
-
New York
-
New York, New York, Forenede Stater, 10065
- Ikke rekrutterer endnu
- Weill Cornell Medicine
-
New York, New York, Forenede Stater, 10029
- Ikke rekrutterer endnu
- Mount Sinai School of Medicine
-
New York, New York, Forenede Stater, 10021
- Ikke rekrutterer endnu
- Memorial Sloan Kettering Cancer Center
-
-
North Carolina
-
Chapel Hill, North Carolina, Forenede Stater, 27514
- Rekruttering
- University of North Carolina At Chapel Hill
-
Charlotte, North Carolina, Forenede Stater, 28204
- Ikke rekrutterer endnu
- Levine Cancer Institute
-
Durham, North Carolina, Forenede Stater, 27705
- Ikke rekrutterer endnu
- Duke University Medical Center, Department of Hematologic Malignancies and Cellular Therapy
-
-
Ohio
-
Cleveland, Ohio, Forenede Stater, 44195
- Ikke rekrutterer endnu
- Cleveland Clinic
-
Columbus, Ohio, Forenede Stater, 43210
- Rekruttering
- Ohio State University
-
-
Tennessee
-
Nashville, Tennessee, Forenede Stater, 37203
- Rekruttering
- Tristar Bmt/Tcto
-
-
Texas
-
Houston, Texas, Forenede Stater, 77030
- Ikke rekrutterer endnu
- University of Texas M. D. Anderson Cancer Center
-
-
Utah
-
Salt Lake City, Utah, Forenede Stater, 84112
- Ikke rekrutterer endnu
- Huntsman Cancer Institute
-
-
Wisconsin
-
Milwaukee, Wisconsin, Forenede Stater, 53226
- Ikke rekrutterer endnu
- Medical College of Wisconsin
-
-
-
-
-
Bordeaux, Frankrig, 33076
- Rekruttering
- Francois-Xavier
-
Paris, Frankrig, 75010
- Rekruttering
- Hospital Saint Louis
-
Villejuif, Frankrig, 94805
- Rekruttering
- Institut Gustave Roussy
-
-
-
-
-
Bologna, Italien, 40138
- Ikke rekrutterer endnu
- Aou Policlinico S. Orsola-Malpighi
-
Milan, Italien, 20122
- Ikke rekrutterer endnu
- Fondazione Irccs Ca' Granda - Ospedale Maggiore Policlinico
-
Roma, Italien, 00168
- Ikke rekrutterer endnu
- A. Gemelli University Hospital, Catholic University of the Sacred Heart
-
Udine, Italien, 33100
- Ikke rekrutterer endnu
- Azienda Sanitaria Universitaria Friuli Centrale Asu Fc
-
-
-
-
-
Kashiwa Chiba, Japan, 277-0882
- Ikke rekrutterer endnu
- National Cancer Center Hospital East
-
Toon, Ehime, Japan, 791-0204
- Ikke rekrutterer endnu
- Ehime University Hospital
-
-
-
-
-
Badalona, Spanien, 08916
- Ikke rekrutterer endnu
- Hospital Universitari Germans Trias I Pujol
-
Las Palmas de Gran Canaria, Spanien, 35010
- Ikke rekrutterer endnu
- Hospital Universitario de Gran Canaria Dr. Negrin
-
Madrid, Spanien, 28041
- Ikke rekrutterer endnu
- Hospital Universitario 12 de Octubre
-
-
-
-
-
Jongno-gu, Seoul, Sydkorea, 03080
- Ikke rekrutterer endnu
- Seoul National University Hospital
-
Seocho-gu, Seoul, Sydkorea, 06591
- Ikke rekrutterer endnu
- The Catholic University of Korea Seoul St. Mary'S Hospital
-
-
-
-
-
Aachen, Tyskland, D-52074
- Rekruttering
- University Medical Center Rwth Aachen
-
Berlin, Tyskland, 10117
- Rekruttering
- Charite Universitaetsmedizin Berlin - Campus Charite Mitte
-
Freiburg im Breisgau, Tyskland, 79106
- Rekruttering
- Universitatklinikum Freiburg
-
Halle, Tyskland, 06120
- Rekruttering
- Universitatsklinikum Halle (Saale)
-
Mainz, Tyskland, 55131
- Ikke rekrutterer endnu
- Universitatsmedizin Der Johannes Gutenberg-Universitat Mainz Iii
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Life expectancy > 6 months.
- Willingness to undergo a pretreatment and limited on-study BM biopsies and aspirates (as appropriate to disease).
- Participants with MF, PV and ET as defined in the protocol.
Exclusion Criteria:
- Presence of any hematological malignancy other than MF, PV, or ET.
- Malignancy within the last 3 years prior to enrollment.
- Acute or chronic HBV, Active HCV or known HIV or tuberculosis infection.
- Clinically significant or uncontrolled cardiac disease.
- Has undergone any prior allogeneic stem-cell transplantation or such transplantation is planned in the next 6 months.
- Laboratory values outside the Protocol-defined ranges.
- Prior history of major bleeding or thrombosis within the last 3 months prior to study enrollment.
- Presence of chronic or current active infectious disease requiring systemic treatment.
- Treatment with an MPN-directed therapy (approved or investigational) within the per protocol threshold before the administration of study drug.
- Prior radiation therapy within 28 days before the first dose of study treatment.
Other protocol-defined Inclusion/Exclusion Criteria may apply.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Sekventiel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Part 1a: Dose Escalation
INCA036978 will be administered at a protocol defined starting regimen as monotherapy to identify the MTD and/or RDE(s). |
INCA036978 will be administered at protocol defined dose. |
|
Eksperimentel: Part 1b: Dose Escalation
INCA036978 will be administered at a protocol defined starting regimen in combination with a standard disease-directed therapy to identify the MTD and/or RDE(s). |
INCA036978 will be administered at protocol defined dose. A standard disease-directed therapy will be administered according to Prescribing Information/SmPC. |
|
Eksperimentel: Part 2a: Dose Expansion
INCA036978 will be administered as monotherapy at the RDE(s) identified during Part 1 |
INCA036978 will be administered at protocol defined dose. |
|
Eksperimentel: Part 2b: Dose Expansion
INCA036978 will be administered in combination with a standard disease-directed therapy at the RDE(s) identified during Part 1. |
INCA036978 will be administered at protocol defined dose. A standard disease-directed therapy will be administered according to Prescribing Information/SmPC. |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Number of participants with Dose Limiting Toxicities (DLT)s in Part 1
Tidsramme: Up to 28 days
|
Dose-limiting toxicity will be defined as the occurrence of any of the toxicities as per protocol. |
Up to 28 days
|
|
Number of participants with Treatment-emergent Adverse Events (TEAEs)
Tidsramme: Up to approximately 2 years
|
Defined as adverse events AE (either reported for the first time or the worsening of a pre-existing event) occurring after the first dose of study drug and up to 60 days after last dose of study drug or until the start of a new disease-directed therapy, whichever occurs first. |
Up to approximately 2 years
|
|
Number of participants with TEAEs leading to dose modification or discontinuation
Tidsramme: Up to approximately 2 years
|
Number of participants with TEAEs leading to study drug modifications (interruptions, dose reduction) or discontinuation. |
Up to approximately 2 years
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Pharmacokinetics Parameter: Cmax of INCA036978
Tidsramme: Up to approximately 2 years
|
Defined as maximum observed plasma concentration of INCA036978. |
Up to approximately 2 years
|
|
Pharmacokinetics Parameter: Tmax of INCA036978
Tidsramme: Up to approximately 2 years
|
Defined as the time to reach the maximum plasma concentration of INCA036978. |
Up to approximately 2 years
|
|
Pharmacokinetics Parameter: Cmax,ss of INCA036978
Tidsramme: Up to approximately 2 years
|
Defined as the maximum observed plasma concentration at steady state of INCA036978. |
Up to approximately 2 years
|
|
Pharmacokinetics Parameter: Cmin,ss of INCA036978
Tidsramme: Up to approximately 2 years
|
Defined as the minimum observed plasma concentration at steady state of INCA036978. |
Up to approximately 2 years
|
|
Pharmacokinetics Parameter: AUC(0-t) of INCA036978
Tidsramme: Up to approximately 2 years
|
Defined as the area under the concentration-time curve up to the last measurable concentration of INCA036978. |
Up to approximately 2 years
|
|
Pharmacokinetics Parameter: AUC 0-∞ of INCA036978
Tidsramme: Up to approximately 2 years
|
Defined as the area under the concentration-time curve from 0 to infinity of INCA036978. |
Up to approximately 2 years
|
|
Pharmacokinetics Parameter: CL/F of INCA036978
Tidsramme: Up to approximately 2 years
|
Defined as the apparent clearance of INCA036978. |
Up to approximately 2 years
|
|
Pharmacokinetics Parameter: Vz/F of INCA036978
Tidsramme: Up to approximately 2 years
|
Defined as the apparent volume of distribution of INCA036978. |
Up to approximately 2 years
|
|
Pharmacokinetics Parameter: t1/2 of INCA036978
Tidsramme: Up to approximately 2 years
|
Defined as the apparent terminal phase disposition half-life of INCA036978. |
Up to approximately 2 years
|
|
For participants with myelofibrosis (MF): Percentage of participants achieving spleen volume reduction as defined in the protocol
Tidsramme: Week 12 and Week 24
|
Defined as percentage of participants with a protocol defined spleen volume reduction. |
Week 12 and Week 24
|
|
For participants with MF and anemia: Anemia Response as defined in the protocol
Tidsramme: Up to approximately 2 years
|
For non transfusion-dependent (TD) participants: An Hb increase relative to baseline as defined in the protocol if non-TD at baseline. For TD participants: Achieving transfusion independency (TI) as defined in the protocol. |
Up to approximately 2 years
|
|
For participants with polycythemia vera (PV): Peripheral blood count remission as defined by the protocol.
Tidsramme: Up to approximately 2 years
|
Peripheral blood count remission as defined by the protocol. |
Up to approximately 2 years
|
|
For participants with essential thrombocythemia (ET): Peripheral blood count remission as defined by the protocol.
Tidsramme: Up to approximately 2 years
|
Peripheral blood count remission as defined by the protocol. |
Up to approximately 2 years
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Studieleder: Incyte Medical Monitor, Incyte Corporation
Publikationer og nyttige links
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Neoplasmer efter sted
- Neoplasmer
- Hæmatologiske sygdomme
- Blodkoagulationsforstyrrelser
- Knoglemarvssygdomme
- Hæmoragiske lidelser
- Blodpladeforstyrrelser
- Knoglemarvsneoplasmer
- Hæmatologiske neoplasmer
- Hemiske og lymfatiske sygdomme
- Trombocytose
- Myeloproliferative lidelser
- Trombocytæmi, essentiel
- Polycytæmi Vera
- Primær myelofibrose
Andre undersøgelses-id-numre
- INCA036978-101
- 2026-525217-31-00 (Registry Identifier: EU CT Number)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .